Breast Cancer in Transgenders: Narrative Review
Open Access
- 28 July 2022
- journal article
- review article
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 45 (01) , 003-008
Abstract
The molecular pathogenesis of breast cancer (BC), the second most common cancer, varies significantly between sexes, with minimal data in the transgender population. The overall prevalence of BC in transgenders is estimated to be 0.02%. Besides experiencing social disparities, transgenders have to face a lot of discrimination in the healthcare system. Adversities faced, along with the urge to identify with physical attributes to the gender felt by them, forces transgenders to use non-prescribed hormones. Gender affirming hormone therapy (GAHT) is a key feature of transition-related care, rehabbing mental health, and the quality of life of transgenders, but at the expense of their health. Studies have reported that GAHT is associated with severe health conditions such as cancer in transgenders. Estrogens and testosterone are associated with a moderate risk of developing BC. The types of BC diagnosed in transgenders after cross-sex hormone therapy include invasive ductal and neuroendocrine carcinoma, in addition to tubular adenocarcinoma. Although diagnosed at an age earlier compared with ciswomen, BC screening recommendations for transgenders are the same as for ciswomen. This review studies in detail the types of transgenders, their characteristics, different types of breast cancers associated, issues faced while treatment, and their best possible solutions. We also hope to have well-designed research in the future, which will fill the existing gaps in knowledge and provide scientific insight into the transgender population and issues related to their health. There are no international guidelines on screening and management of transgender patients but it appears that breast screening before cosmetic mastectomy, exposure to hormonal therapy for more than 5 years, and as per natal women screening guidelines should be offered to the patient with detailed discussion on the harms and benefits of the same.Keywords
This publication has 37 references indexed in Scilit:
- Breast Imaging in the Transgender PatientAmerican Journal of Roentgenology, 2014
- Experiences of Transgender-Related Discrimination and Implications for Health: Results From the Virginia Transgender Health Initiative StudyAmerican Journal of Public Health, 2013
- Nonprescribed Hormone Use and Self-Performed Surgeries: “Do-It-Yourself” Transitions in Transgender Communities in Ontario, CanadaAmerican Journal of Public Health, 2013
- Breast Cancer in Female-to-Male Transsexuals: Two Cases With a Review of Physiology and ManagementClinical Breast Cancer, 2011
- Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual populationReproductive BioMedicine Online, 2010
- Health Care Utilization, Barriers to Care, and Hormone Usage Among Male-to-Female Transgender Persons in New York CityAmerican Journal of Public Health, 2009
- Long-Term Treatment of Transsexuals with Cross-Sex Hormones: Extensive Personal ExperienceThe Journal of Clinical Endocrinology & Metabolism, 2008
- Breast cancer and hormone-replacement therapy: the Million Women StudyThe Lancet, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal WomenNew England Journal of Medicine, 1995